Clinical and Experimental Medicine

, Volume 7, Issue 4, pp 164–172 | Cite as

ApoE ε2/ε3/ε4 polymorphism, ApoC-III/ApoE ratio and metabolic syndrome

  • O. Olivieri
  • N. Martinelli
  • A. Bassi
  • E. Trabetti
  • D. Girelli
  • F. Pizzolo
  • S. Friso
  • P. F. Pignatti
  • R. Corrocher
Original

Abstract

Triglyceride-rich lipoproteins contain both apolipoproteins E (ApoE) and C-III (ApoC-III), which show opposite functional properties. The relationships between the ApoE (ε2/ε3/ε4) gene polymorphism and ApoC-III/ApoE ratio has never been investigated. A large population (n=552) of cardiovascular patients, without diabetes and/or lipid-lowering therapy, with or without metabolic syndrome (MetSyn), was genotyped for ε2/ε3/ε4 polymorphism and their ApoCIII/ApoE ratio was evaluated. A second group of patients (n=76) with peripheral artery disease was also genotyped and their ApoC-III/ApoE ratios were measured in HDL and non-HDL fractions. Subjects with E2 had higher and E4 carriers lower TG,ApoE and ApoC-III levels, respectively. The ApoCIII/ ApoE ratio showed an opposite trend, gradually increasing from E2/E2 to E4/E4 subjects. MetSyn patients also had an elevated ApoC-III/ApoE ratio and E4 carriers were more frequent in MetSyn patients (OR 2.08 with a 95%CI 1.22–3.5). The distribution of ApoC-III/ApoE ratio was confirmed also in the second group, with lower values in E2/E3 and higher in E3/E4 subjects. Similar results were obtained for the concentrations measured in non-HDL fractions, but not in the HDL fractions. ApoE ε2/ε/ε4 gene polymorphism is a determinant of the relative proportion of apolipoprotein C-III to E. Carriers of the unfavourable E4 allele present the highest ApoCIII/ApoE ratio and are twofold more frequent among individuals affected by MetSyn.

Key words

ApoE genotype Metabolic syndrome ApoC-III/ApoE ratio 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Song Y, Stampfer MJ, Liu S (2004) Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 141:137–147PubMedGoogle Scholar
  2. 2.
    Paik YK, Chang DJ, Reardon CA et al (1985) Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci U S A 82:3445–3449PubMedCrossRefGoogle Scholar
  3. 3.
    Greenow K, Pearce NJ, Ramji DP (2005) The key role of apolipoprotein E in atherosclerosis. J Mol Med 83:329–342PubMedCrossRefGoogle Scholar
  4. 4.
    Mahley RW, Rall SC Jr (2000) Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1:507–537PubMedCrossRefGoogle Scholar
  5. 5.
    Dallongeville J, Lussier-Cacan S, Davignon J (1992) Modulation of plasma triglyceride levels by ApoE phenotype: a meta-analysis. J Lipid Res 33:447–454PubMedGoogle Scholar
  6. 6.
    Ordovas JM, Schaefer EJ (2000) Genetic determinants of plasma lipid response to dietary intervention: the role of the APOA1/C3/A4 gene cluster and the ApoE gene. Br J Nutr 83[Suppl 1]:S127–136PubMedGoogle Scholar
  7. 7.
    Mahley RW, Ji ZS (1999) Remnant lipoprotein metabolism: key pathways involving cell-surface heparin sulfate proteoglycans and apolipoprotein E. J Lipid Res 40:1–16PubMedGoogle Scholar
  8. 8.
    van den Elzen P, Garg S, Leon L et al (2005) Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437:906–910PubMedCrossRefGoogle Scholar
  9. 9.
    Zhang SH, Reddick RL, Piedrahita JA, Maeda N (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468–471PubMedCrossRefGoogle Scholar
  10. 10.
    Zhang SH, Reddick RL, Burkey B, Maeda N (1994) Dietinduced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest 94:937–945PubMedCrossRefGoogle Scholar
  11. 11.
    Meir KS, Leitersdorf E (2004) Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 24:1006–1014PubMedCrossRefGoogle Scholar
  12. 12.
    Morrow JA, Segall ML, Lund-Katz S et al (2000) Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. Biochemistry 39:11657–11666PubMedCrossRefGoogle Scholar
  13. 13.
    Cohn JS, Marcoux C, Davignon J (1999) Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 19:2474–2486PubMedGoogle Scholar
  14. 14.
    Sing CF, Davignon J (1985) Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 37:268–285PubMedGoogle Scholar
  15. 15.
    Jong MC, Hofker MH, Havekes LM (1999) Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19:472–484PubMedGoogle Scholar
  16. 16.
    McConathy WJ, Gesquiere JC, Bass H et al (1992) Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 33:995–1003PubMedGoogle Scholar
  17. 17.
    Ginsberg HN, Le NA, Goldberg IJ et al (1986) Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 78:1287–1295PubMedCrossRefGoogle Scholar
  18. 18.
    Kawakami A, Aikawa M, Alcaide P et al (2006) Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 114:681–687PubMedCrossRefGoogle Scholar
  19. 19.
    Hodis HN, Mack WJ (1998) Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J 19[Suppl A]:A40–44PubMedGoogle Scholar
  20. 20.
    Sacks FM, Alaupovic P, Moye LA et al (2000) VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102:1886–1892PubMedGoogle Scholar
  21. 21.
    Cohn JS, Patterson BW, Uffelman KD et al (2004) Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab 89:3949–3955PubMedCrossRefGoogle Scholar
  22. 22.
    Olivieri O, Stranieri C, Bassi A et al (2002) ApoC-III gene polymorphisms and risk of coronary artery disease. J Lipid Res 43:1450–1457PubMedCrossRefGoogle Scholar
  23. 23.
    Olivieri O, Bassi A, Stranieri C et al (2003) Apolipoprotein CIII, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 44:2374–2381PubMedCrossRefGoogle Scholar
  24. 24.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRefGoogle Scholar
  25. 25.
    Zee RY, Cook NR, Cheng S et al (2004) Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum Mol Genet 13:389–396PubMedCrossRefGoogle Scholar
  26. 26.
    Eichner JE, Dunn ST, Perveen G et al (2002) Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155:487–495PubMedCrossRefGoogle Scholar
  27. 27.
    Scuteri A, Najjar SS, Muller D et al (2005) ApoE4 allele and the natural history of cardiovascular risk factors. Am J Physiol Endocrinol Metab 289:E322–327PubMedCrossRefGoogle Scholar
  28. 28.
    Hallman DM, Boerwinkle E, Saha N et al (1991) The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 49:338–349PubMedGoogle Scholar
  29. 29.
    Hiukka A, Fruchart-Najib J, Leinonen E et al (2005) Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia 48:1207–1215PubMedCrossRefGoogle Scholar
  30. 30.
    Tian Y, Long SY, Xu YH et al (2005) Study on ApoE gene polymorphism and subclasses of serum high density lipoprotein in type IV hyperlipidemia [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22:96–98PubMedGoogle Scholar
  31. 31.
    Tilly P, Sass C, Vincent-Viry M et al (2003) Biological and genetic determinants of serum apolipoprotein CIII concentration. Reference limits from the Stanislas Cohort. J Lipid Res 44:430–436PubMedCrossRefGoogle Scholar
  32. 32.
    Stephan ZF, Gibson JC, Hayes KC (1986) The apo E/apo CIII molar ratio affects removal of cholesterol ester from modified human lipoproteins injected into cebus monkeys. Life Sci 38:1383–1392PubMedCrossRefGoogle Scholar
  33. 33.
    Gregg RE, Zech LA, Schaefer EJ et al (1986) Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 78:815–821PubMedCrossRefGoogle Scholar
  34. 34.
    Bergeron N, Havel RJ (1996) Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein epsilon 4 allele. J Clin Invest 97:65–72PubMedCrossRefGoogle Scholar
  35. 35.
    Cardona F, Morcillo S, Gonzalo-Marin M, Tinahones FJ (2005) The apolipoprotein E genotype predicts postprandial hypertriglyceridemia in patients with the metabolic syndrome. J Clin Endocrinol Metab 90:2972–2975PubMedCrossRefGoogle Scholar
  36. 36.
    Stiefel P, Montilla C, Muniz-Grijalvo O et al (2001) Apolipoprotein E gene polymorphism is related to metabolic abnormalities, but does not influence erythrocyte membrane lipid composition or sodium-lithium countertransport activity in essential hypertension. Metabolism 50:157–160PubMedCrossRefGoogle Scholar
  37. 37.
    de Knijff P, Boomsma DI, Feskens EJ et al (1994) Apolipoprotein E phenotype and blood pressure. Lancet 343:1234–1235PubMedCrossRefGoogle Scholar
  38. 38.
    Uusitupa M, Sarkkinen E, Kervinen K, Kesaniemi YA (1994) Apolipoprotein E phenotype and blood pressure. Lancet 343:57PubMedCrossRefGoogle Scholar
  39. 39.
    Yilmaz H, Isbir T, Agachan B, Aydin M (2001) Is epsilon4 allele of apolipoprotein E associated with more severe endorgan damage in essential hypertension? Cell Biochem Funct 19:191–195PubMedCrossRefGoogle Scholar
  40. 40.
    Li X, Du Y, Du Y, Huang X (2003) Association of apolipoprotein E gene polymorphism with essential hypertension and its complications. Clin Exp Med 2:175–179PubMedCrossRefGoogle Scholar
  41. 41.
    Paris D, Town T, Parker TA et al (1998) Isoform-specific vasoconstriction induced by apolipoprotein E and modulation of this effect by Alzheimer’s beta-amyloid peptide. Neurosci Lett 256:73–76PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2007

Authors and Affiliations

  • O. Olivieri
    • 1
  • N. Martinelli
    • 1
  • A. Bassi
    • 2
  • E. Trabetti
    • 3
  • D. Girelli
    • 1
  • F. Pizzolo
    • 1
  • S. Friso
    • 1
  • P. F. Pignatti
    • 3
  • R. Corrocher
    • 1
  1. 1.Unit of Internal Medicine, Department of Clinical and Experimental Medicine, Cattedra di Medicina InternaUniversity of VeronaVeronaItaly
  2. 2.Institute of Clinical ChemistryUniversity of VeronaVeronaItaly
  3. 3.Section of Biology and Genetics, Department of Mother and Child and Biology — GeneticsUniversity of VeronaVeronaItaly

Personalised recommendations